华兰疫苗
(301207)
| 流通市值：117.13亿 | | | 总市值：117.20亿 |
| 流通股本：6.01亿 | | | 总股本：6.01亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 26,775,352.59 | 1,202,505,820.54 | 805,986,896.84 | 59,961,774.27 |
| 营业收入 | 26,775,352.59 | 1,202,505,820.54 | 805,986,896.84 | 59,961,774.27 |
| 二、营业总成本 | 48,488,924.09 | 1,021,513,204.01 | 757,546,402.98 | 163,447,081.23 |
| 营业成本 | 7,786,364.4 | 266,941,314.06 | 185,428,235.39 | 14,837,205.7 |
| 税金及附加 | 1,575,601.62 | 10,239,569.21 | 7,074,963.95 | 2,848,922.88 |
| 销售费用 | 11,699,486.26 | 544,474,956.02 | 401,311,273.85 | 28,993,900.37 |
| 管理费用 | 6,946,003.55 | 50,323,036.8 | 52,945,493.02 | 34,538,407.88 |
| 研发费用 | 20,775,324.78 | 151,302,562.02 | 111,781,220.66 | 82,323,158.68 |
| 财务费用 | -293,856.52 | -1,768,234.1 | -994,783.89 | -94,514.28 |
| 其中:利息费用 | - | 2,550,000.02 | 2,550,000.02 | 2,550,000.02 |
| 其中:利息收入 | 318,173.62 | 4,444,764.66 | 3,646,881.27 | 2,729,855.27 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,066,763.04 | 12,726,022.07 | 15,112,478.66 | 10,279,395.19 |
| 加:投资收益 | 14,719,086.04 | 76,806,684.63 | 55,500,965.39 | 39,067,003.76 |
| 资产处置收益 | - | -204,773.66 | -24,955.08 | - |
| 资产减值损失(新) | 200,043.72 | -58,207,765.52 | 12,277,453.7 | 12,277,453.7 |
| 信用减值损失(新) | 41,591,811.05 | -30,713,440.61 | 1,921,489.59 | 49,290,397.91 |
| 其他收益 | 1,634,717.36 | 8,376,400.04 | 6,123,690.36 | 4,701,403.79 |
| 四、营业利润 | 40,498,849.71 | 189,775,743.48 | 139,351,616.48 | 12,130,347.39 |
| 加:营业外收入 | 1,374.09 | 212,240 | 210,000 | 208,000 |
| 减:营业外支出 | 29,874.64 | 2,202,055.93 | 1,933,605.57 | 1,136,403.45 |
| 五、利润总额 | 40,470,349.16 | 187,785,927.55 | 137,628,010.91 | 11,201,943.94 |
| 减:所得税费用 | 3,104,636.41 | 4,866,236.71 | 5,319,410.86 | -9,595,212.86 |
| 六、净利润 | 37,365,712.75 | 182,919,690.84 | 132,308,600.05 | 20,797,156.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 37,365,712.75 | 182,919,690.84 | 132,308,600.05 | 20,797,156.8 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 37,365,712.75 | 182,919,690.84 | 132,308,600.05 | 20,797,156.8 |
| 扣除非经常损益后的净利润 | 26,147,410.97 | 131,684,243.98 | 86,255,749.63 | -12,784,853.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.31 | 0.22 | 0.04 |
| (二)稀释每股收益 | 0.06 | 0.31 | 0.22 | 0.04 |
| 九、综合收益总额 | 37,365,712.75 | 182,919,690.84 | 132,308,600.05 | 20,797,156.8 |
| 归属于母公司股东的综合收益总额 | 37,365,712.75 | 182,919,690.84 | 132,308,600.05 | 20,797,156.8 |
| 公告日期 | 2026-04-27 | 2026-03-28 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |